Current Advances in RNA Therapeutics for Human Diseases
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Following the discovery of nucleic acids by Friedrich Miescher in 1868, DNA and RNA were recognized as the genetic code containing the necessary information for proper cell functioning. In the years following these discoveries, vast knowledge of the seemingly endless roles of RNA have become better understood. Additionally, many new types of RNAs were discovered that seemed to have no coding properties (non-coding RNAs), such as microRNAs (miRNAs). The discovery of these new RNAs created a new avenue for treating various human diseases. However, RNA is relatively unstable and is degraded fairly rapidly once administered; this has led to the development of novel delivery mechanisms, such as nanoparticles to increase stability as well as to prevent off-target effects of these molecules. Current advances in RNA-based therapies have substantial promise in treating and preventing many human diseases and disorders through fixing the pathology instead of merely treating the symptomology similarly to traditional therapeutics. Although many RNA therapeutics have made it to clinical trials, only a few have been FDA approved thus far. Additionally, the results of clinical trials for RNA therapeutics have been ambivalent to date, with some studies demonstrating potent efficacy, whereas others have limited effectiveness and/or toxicity. Momentum is building in the clinic for RNA therapeutics; future clinical care of human diseases will likely comprise promising RNA therapeutics. This review focuses on the current advances of RNA therapeutics and addresses current challenges with their development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 5×
“BNT162b2 IM Immunogenicity and antibody response to SARS-CoV-2 S antigens SARS-CoV-2 S antigens’ expression COVID-19 BioNTech and Pfizer FDA (2020) [31]”
BackgroundInfluentialEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Wightman, B., Ha, I., & Ruvkun, G. (1993) · Cell · doi:10.1016/0092-8674(93)90530-4 · Cited by 4,292
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 1×
“in vivo through the injection of a synthetic mRNA that encoded beta-galactosidase, chloramphenicol, or luciferase into the skeletal muscle of mice [72].”
BackgroundPatisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 2×
“Pegaptanib Intravitreal Heparinbinding domain of VEGF-165 Blocking VEGF-165 Neovascular age-related macular degeneration OSI Pharmaceuticals FDA (2004) [28]”
BackgroundTowards a molecular understanding of microRNA-mediated gene silencing
Jonas, S., & Izaurralde, E. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3965 · Cited by 1,872
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551 · cited 2×
“For years it was believed that DNA was transcribed into RNA and that this RNA (messenger RNA) was then translated into a protein; however, this all became more complicated when RNA interference (RNAi) was discovered [1,2].”
BackgroundNusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433 · cited 2×
“Nusinersen modulates splicing of SMN2, which varies only from SMN1 in that it undergoes alternative splicing and excludes exon 7 [16].”
BackgroundAge-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes
Matranga, C., Tomari, Y., Shin, C., Bartel, D. P., & Zamore, P. D. (2005) · Cell · doi:10.1016/j.cell.2005.08.044 · Cited by 1,211
MicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3313 · Cited by 1,156
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2537-9 · Cited by 1,052 · cited 2×
“BNT111 IV Targets four non-mutated, TAAs (NY-ESO-1, MAGEA3, tyrosinase and TPTE Induction of immune response against the four selected malignant melanomaassociated antigens (New York-ESO 1 (NY-ESO-1), tyrosinase, Melanomaassociated antigen A3 (MAGE-A3), and Trans-membrane phosphatase with tensin homology (TPTE)) Advan…”
BackgroundMethodMicroRNAs 103 and 107 regulate insulin sensitivity
Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B., Akin, A., Zavolan, M., Heim, M. H., & Stoffel, M. (2011) · Nature · doi:10.1038/nature10112 · Cited by 1,000 · cited 6×
“Further, preclinical studies have demonstrated that a miR-103/107 inhibitor can improve insulin sensitivity in obese mice [62].”
BackgroundInfluentialUntranslated regions of mRNAs.
(2002) · Genome biology · doi:10.1186/gb-2002-3-3-reviews0004 · Cited by 987
Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them
Leppek, K., Das, R., & Barna, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.103 · Cited by 949 · cited 1×
“mRNAs are typically around 2 kb in length and characteristically contain a 5′ cap, 5′ UTR, coding region, 3′ UTR, and poly(A) tail (Figure 1A) [69].”
BackgroundLu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
Musunuru, K., Chadwick, A. C., Mizoguchi, T., Garcia, S. P., DeNizio, J. E., Reiss, C. W., Wang, K., Iyer, S., Dutta, C., Clendaniel, V., et al. (2021) · Nature · doi:10.1038/s41586-021-03534-y · Cited by 793
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy
Ucar, A., Gupta, S. K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., Dangwal, S., Kumarswamy, R., Bang, C., Holzmann, A., et al. (2012) · Nature Communications · doi:10.1038/ncomms2090 · Cited by 610
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Windyga, J., Anderson, K. E., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913147 · Cited by 608
Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA
Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillet, J., Lévy, J., & Meulien, P. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230749 · Cited by 473 · cited 1×
“, reported that there was induction of anti-influenza cytotoxic T lymphocytes following immunization with liposome-complexed mRNA-encoding influenza virus nucleoproteins in a murine model [74].”
BackgroundPetsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 464
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., Jamieson, A. M., Langdon, W. Y., Ikeda, F., Fededa, J. P., et al. (2014) · Nature · doi:10.1038/nature12998 · Cited by 456
Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203938 · Cited by 396
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336 · cited 15×
“ARRx (AZD5312) has undergone Phase I/II testing for the treatment of CRPC [37].”
BackgroundInfluentialMutant KRAS is a druggable target for pancreatic cancer
Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295 · cited 14×
“ARRx (AZD5312) has undergone Phase I/II testing for the treatment of CRPC [37].”
BackgroundInfluentialReversal of Diabetes Insipidus in Brattleboro Rats: Intrahypothalamic Injection of Vasopressin mRNA
Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D., & Bloom, F. E. (1992) · Science · doi:10.1126/science.1546298 · Cited by 282 · cited 1×
“, used mRNA to treat diabetes insipidus in Brattleboro rats that have reduced levels of vasopressin [73].”
BackgroundSystemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263 · cited 16×
“ARRx (AZD5312) has undergone Phase I/II testing for the treatment of CRPC [37].”
BackgroundMethodInfluentialSchnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 230
John, S., Yuzhakov, O., Woods, A., Deterling, J., Hassett, K., Shaw, C. A., & Ciaramella, G. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.01.029 · Cited by 229
Aldrich, C., Leroux–Roels, I., Huang, K. B., Bica, M. A., Loeliger, E., Schoenborn-Kellenberger, O., Walz, L., Leroux-Roels, G., von Sonnenburg, F., & Oostvogels, L. (2021) · Vaccine · doi:10.1016/j.vaccine.2020.12.070 · Cited by 213 · cited 1×
“The second vaccine candidate is CV7202 and is in Phase I clinical trials for rabies prevention [75].”
BackgroundKremsner, P. G., Ahuad Guerrero, R. A., Arana-Arri, E., Aroca Martinez, G. J., Bonten, M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00677-0 · Cited by 172 · cited 5×
“This vaccine candidate is produced by CureVac AG and is a chemically unmodified mRNA that encodes the full-length S protein of SARS-CoV-2 and utilizes the RNActive mRNA vaccine platform [52].”
BackgroundMethodInfluentialZhu, X., Yin, L., Theisen, M., Zhuo, J., Siddiqui, S., Levy, B., Presnyak, V., Frassetto, A., Milton, J., Salerno, T., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.003 · Cited by 165
Aliprantis, A. O., Shaw, C. A., Griffin, P., Farinola, N., Railkar, R. A., Cao, X., Liu, W., Sachs, J. R., Swenson, C. J., Lee, H., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1829899 · Cited by 149
miR-10b-5p Rescues Diabetes and Gastrointestinal Dysmotility
Singh, R., Ha, S. E., Wei, L., Jin, B., Zogg, H., Poudrier, S. M., Jorgensen, B. G., Park, C., Ronkon, C. F., Bartlett, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.062 · Cited by 86
Self-citationde Paula Brandão, P. R., Titze-de-Almeida, S. S., & Titze-de-Almeida, R. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00438-6 · Cited by 72
mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency
Cao, J., An, D., Galduroz, M., Zhuo, J., Liang, S., Eybye, M., Frassetto, A., Kuroda, E., Funahashi, A., Santana, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.017 · Cited by 70
Cortes, J., Kantarjian, H., Ball, E. D., DiPersio, J., Kolitz, J. E., Fernandez, H. F., Goodman, M., Borthakur, G., Baer, M. R., & Wetzler, M. (2012) · Cancer · doi:10.1002/cncr.26292 · Cited by 37
Cited by
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
The landscape of nanoparticle-based siRNA delivery and therapeutic development
Moazzam, M., Zhang, M., Hussain, A., Yu, X., Huang, J., & Huang, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.005 · Cited by 230
Metadata
- Authors
- Zogg, H., Singh, R., & Ro, S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-03-01
- Volume
- 23
- Issue
- 5
- Pages
- 2736
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4214669202
- Cited by
- 172
- References
- 40
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.